1,102,961 Shares in QIAGEN N.V. $QGEN Bought by Nuveen LLC

Key Points

• Nuveen LLC has invested approximately $44.08 million in Qiagen N.V., acquiring over 1.1 million shares, representing 0.50% ownership of the company.
• Qiagen reported earnings of $0.60 per share for the last quarter, meeting expectations, while revenue increased by 7.7% year over year to $533.54 million.
• The company recently declared a $0.25 dividend, with a current dividend yield of 52.0%, indicating a relatively low payout ratio of 14.79%.

Nuveen LLC acquired a new stake in QIAGEN N.V. (NYSE:QGEN - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,102,961 shares of the company's stock, valued at approximately $44,078,000. Nuveen LLC owned about 0.50% of QIAGEN at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Invesco Ltd. grew its stake in shares of QIAGEN by 13.5% in the first quarter. Invesco Ltd. now owns 449,638 shares of the company's stock valued at $18,053,000 after acquiring an additional 53,383 shares in the last quarter. Forsta AP Fonden lifted its position in QIAGEN by 185.8% during the first quarter. Forsta AP Fonden now owns 29,368 shares of the company's stock worth $1,179,000 after purchasing an additional 19,093 shares during the period. Citigroup Inc. lifted its position in QIAGEN by 51.4% during the first quarter. Citigroup Inc. now owns 473,388 shares of the company's stock worth $18,754,000 after purchasing an additional 160,799 shares during the period. Caisse Des Depots ET Consignations lifted its position in QIAGEN by 7.3% during the first quarter. Caisse Des Depots ET Consignations now owns 1,345,657 shares of the company's stock worth $53,374,000 after purchasing an additional 91,357 shares during the period. Finally, Deutsche Bank AG lifted its position in QIAGEN by 57.5% during the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after purchasing an additional 1,639,621 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

QIAGEN Stock Performance

Shares of NYSE QGEN traded up $0.0390 during mid-day trading on Thursday, reaching $49.2390. 126,716 shares of the company's stock were exchanged, compared to its average volume of 1,369,943. The firm has a market capitalization of $10.95 billion, a price-to-earnings ratio of 29.10, a price-to-earnings-growth ratio of 2.58 and a beta of 0.64. QIAGEN N.V. has a 52 week low of $37.63 and a 52 week high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The firm has a 50-day moving average price of $48.53 and a two-hundred day moving average price of $43.81.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting the consensus estimate of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. During the same quarter last year, the firm posted $0.55 EPS. The firm's revenue for the quarter was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Analysts predict that QIAGEN N.V. will post 2.26 EPS for the current year.

QIAGEN Announces Dividend

The business also recently announced a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a dividend of $0.25 per share. This represents a yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's payout ratio is presently 14.79%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on QGEN shares. Wall Street Zen cut shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. Bank of America increased their target price on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Cowen reissued a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. UBS Group increased their target price on shares of QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Finally, Barclays assumed coverage on QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $49.69.

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.